Bli medlem
Bli medlem

Du är här

2015-04-14

Bio-Reference Laboratories, Inc. : BioReference Laboratories Partners With Organizations Accelerating Medical Innovation

* Launches first Global Alliance for Genomics and Health Beacon by a
commercial laboratory
* Presenting at Pistoia Alliance Spring Conference 2015 being held in Zurich,
Switzerland

ELMWOOD PARK, N.J., April 14, 2015 (GLOBE NEWSWIRE) -- BioReference
Laboratories, Inc. (Nasdaq:BRLI) announced today that it has joined two
leading organizations that are focused on accelerating pharmaceutical R&D and
medical innovation through collaboration, data sharing and best practices -
the Pistoia Alliance, as a Participating Member, and the Global Alliance for
Genomics and Health (GA4GH) as an Organizational Member.

The Pistoia Alliance is a global, not-for-profit alliance of more than 80 life
science companies, vendors, publishers, academic groups, and individuals that
work together to lower barriers to innovation in R&D. The projects that the
Pistoia Alliance works on helps transform R&D innovation through
pre-competitive collaboration and brings together the key constituents to
identify the root causes that lead to R&D inefficiencies. The organization
develops best practices and technology pilots to overcome common obstacles
and the members collaborate as equals on open projects that generate
significant value for the worldwide life sciences community. Joe Donahue,
Senior Vice President, BioReference Laboratories will be presenting at the
Pistoia Alliance Spring Conference 2015 being held in Zurich, Switzerland on
April 14, 2015. More information on the Pistoia Alliance can be found at
http://www.pistoiaalliance.org.

GA4GH was formed to help accelerate the potential of genomic medicine to
advance human health. It brings together over 285 leading organizations in 30
countries, including some of the world's leading healthcare providers,
research funders, research institutions, pharmaceutical companies, disease
advocacy organizations, and life science and information technology
companies. GA4GH Members are working together to create a common framework of
harmonized approaches to enable the responsible, voluntary, and secure
sharing of genomic and clinical data. More information on GA4GH is
athttp://www.genomicsandhealth.org.

In addition, BioReference has become the first commercial laboratory to make a
Beacon available to the worldwide medical research community. The Beacon
project is an initiative of the Data Working Group of GA4GH, and the
objective of the project is to test the willingness of international sites to
share basic genetic data. This open web service is designed both to be
technically simple and to not return information that could be construed as
violating anyone's privacy. Initially, BioReference will make available all
gene variants uncovered through whole exome analysis performed by its GeneDx
subsidiary, the world leader in rare disease testing. Additional information
on the Beacon project can be found at http://ga4gh.org/#/beacon and the
BioReference Beacon can be found at http://beacon.bioreference.com/.

"We are delighted to be partnering with the Global Alliance for Genomics and
Health and Pistoia," said Marc Grodman, MD, CEO BioReference Laboratories.
"The data and insights we have been collecting for more than the last 30
years are invaluable for drug discovery and we look forward to working with
our partners in industry, disease foundations, and academia to develop
innovative solutions that help accelerate medical research and improve
patient outcomes and care."

"It is exciting to have a commercial laboratory light up a Beacon so quickly
after joining the Global Alliance for Genomics and Health. They are the 14th
organisation to join the Beacon network that in total includes over 120 sets
of genomic data," said Peter Goodhand, GA4GH Executive Director. "We welcome
BioReference Laboratories as a GA4GH Member and look forward to their
contributions on the Beacon project and other important efforts to advance
the responsible sharing of genomic and health related data."

Michael Braxenthaler, President of the Pistoia Alliance added: "I am pleased
to see the membership of the Pistoia Alliance expand into new areas with the
addition of our first testing laboratory. With many pharmaceutical companies
increasingly engaging with key data providers, it is vital for the Pistoia
Alliance to be linked with these organizations, and only through greater
collaboration can we solve the many challenges facing the life sciences
industry."

About BioReference Laboratories, Inc
.

BioReference Laboratories is one of the largest and fastest growing full
service diagnostic laboratories in the world, providing clinical testing
services to physician offices, clinics, hospitals, long term care facilities
and employers while also advancing drug discovery and development with
disease foundations, academic and pharmaceutical partners. Our comprehensive
testing capabilities and expertise spans molecular diagnostics, anatomical
pathology, women's health, oncology and rare disease genetics. BioReference,
and our subsidiaries, have an international presence in more than 55
countries.

Statements included in this release that are not historical in nature, are
intended to be, and are hereby identified as "forward-looking statements".
Forward-looking statements may be identified by words such as "expects,"
"anticipates," "intends," "plans," "believes," "seeks," "estimates," "will"
or words of similar meaning and include, but are not limited to, statements
about the expected future business and financial performance of Bio-Reference
Laboratories, Inc. and its subsidiaries. Statements looking forward in time
are included in this release pursuant to the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995. Readers are cautioned not
to place undue reliance on forward-looking statements, which speak only as of
the date they are made and which reflect management's current estimates,
projections, expectations or beliefs and which involve risks and
uncertainties that could cause actual results and outcomes to be materially
different. Risks and uncertainties that may affect the future results of the
company include, but are not limited to, the risks and uncertainties detailed
from time to time in our filings with the Securities and Exchange Commission.
We undertake no obligation to publicly update or review any forward-looking
information, whether as a result of new information, future developments or
otherwise.

www.bioreference.com

CONTACT: Tara Mackay, Investor Relations
(201) 791-2600
(201) 791-1941 (fax)
tmackay@bioreference.com

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bio-Reference Laboratories, Inc. via Globenewswire

HUG#1910821

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.